2-azido-6-(hydroxymethyl)oxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-azido-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C6H11N3O5
• mdl: MFCD00982430
• 分子量: 205.17
• InChiKey: KSRDTSABQYNYMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  105
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-azido-6-(hydroxymethyl)oxane-3,4,5-triol 、 在 copper(ll) sulfate pentahydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 以42.8 %的产率得到
  参考文献：
  名称：

  A novel hepatocyte-targeting fluorescent probe of rhodamine analogues to detect hypochlorite in lysosomes: Design, synthesis and evaluation

  摘要：

  DOI：

  10.1016/j.jphotochem.2024.115597

文献信息

• [EN] MODULAR SYNTHESIS OF AMPHIPHILIC JANUS GLYCODENDRIMERS AND THEIR SELF-ASSEMBLY INTO GLYCODENDRIMERSOMES<br/>[FR] SYNTHÈSE MODULAIRE DE GLYCODENDRIMÈRES AMPHIPHILES DE TYPE JANUS ET LEUR AUTOASSEMBLAGE EN GLYCODENDRIMÈRESOMES
  申请人：PERCEC VIRGIL

  公开号：WO2014190024A1

  公开（公告）日：2014-11-27

  The invention concerns compounds of the formula (I) wherein: Y1 and Y2 are independently a monosaccharide or disaccharide; X1 and X2 are independently -(R9-O)m-, -(R10)P-, -O-(R11-O)q-, -R16-O-R17-O- or a covalent bond; Q1 and Q2 are independently a nitrogen-containing heterocycle moiety; Z1 and Z2 are independently -(O-R7)-, -(O-C(=O)-R8)a-, -O-C(=O)-R12-C(=0)-R13-, -O- C(=O)-R14-C(=O)-R15 or a covalent bond; R7-R17 are each independently C1-C6 alkyl; R1-R6 are each independently a linear or branched alkly group; b, c, d, e, f, and g are 0 or 1, provided b + c + d equals at least 2 and e + f + g equals at least 2; and a, m, p, and q are each an integer from 1-6.

  该发明涉及式(I)的化合物，其中：Y1和Y2分别是单糖或二糖；X1和X2分别是-(R9-O)m-，-(R10)P-，-O-(R11-O)q-，-R16-O-R17-O-或共价键；Q1和Q2分别是含氮杂环基；Z1和Z2分别是-(O-R7)-，-(O-C(=O)-R8)a-，-O-C(=O)-R12-C(=0)-R13-，-O- C(=O)-R14-C(=O)-R15或共价键；R7-R17各自独立地是C1-C6烷基；R1-R6各自独立地是线性或支链烷基；b、c、d、e、f和g为0或1，但要求b + c + d至少等于2，e + f + g至少等于2；a、m、p和q各自是1-6的整数。
• [EN] PLINABULIN PRODRUG ANALOGS AND THERAPEUTIC USES THEREOF<br/>[FR] ANALOGUES DE PROMÉDICAMENTS À BASE DE PLINABULINE ET UTILISATIONS THÉRAPEUTIQUES ASSOCIÉES
  申请人：TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES

  公开号：WO2012035436A1

  公开（公告）日：2012-03-22

  Compounds of Formula (I) and (I') are disclosed, as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed. (Formula (I) & (I'))

  公开了式（I）和（I'）的化合物，以及制备这些化合物的方法。还公开了用于治疗包括癌症和与血管增殖相关的非癌症疾病的组合物和方法。（式（I）和（I'））
• Anti-MSR1 antibodies and methods of use thereof
  申请人：REGENERON PHARMACEUTICALS, INC.

  公开号：US11377502B2

  公开（公告）日：2022-07-05

  Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

  本文提供了结合 MSR1 的抗体和抗原结合片段及其使用方法。根据某些实施方案，抗体以高亲和力结合人 MSR1。在某些实施方案中，抗体结合 MSR1 而不阻断或阻断少于 90% 的修饰低密度脂蛋白与 MSR1 的结合。在某些实施方案中，抗体与细胞表面表达的 MSR1 结合并被内化。本发明的抗体可以是全人源抗体。本发明包括与药物或治疗化合物结合的抗MSR1抗体或其抗原结合片段。
• HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：EP3706805A2

  公开（公告）日：2020-09-16
• DERIVATIVES OF ELASTIN-LIKE POLYPEPTIDES AND USES THEREOF
  申请人：Centre national de la Recherche Scientifique

  公开号：US20190135896A1

  公开（公告）日：2019-05-09

  The present invention concerns the use of a thioether alkylation process for modulating the lower critical solution temperature of an elastin-like polypeptide comprising at least one methionine residue. It also concerns derivatives of elastin-like polypeptides and their preparation process.